Transcription
Good morning, everybody. My name is Amr Salahieh and I am the CEO of Shifamed. I'm going to give you just a four or five minute overview of Shifamed. And then I'll introduce each CEO and each company when one after the other. Thank you for having me for LSI. And so, who are we? Shifamed is a medical technology innovation hub. So we start medical device companies and we focus on big clinical needs that really have a big patient outcome. That's really great for their patients, physicians, and ultimately, our investors. We've been really on a high growth rate for the last few years. We have eight active companies, we've raised $295 million over the last three years. We've we continue to file patents, 100, patents, and 450 pending. And we put a lot of effort in our infrastructure. We have 111,000 square feet of facilities, seven facilities and a single campus. We spent $23 million and facilities improvements and capital equipment. And we spent about $10 million a year on improvements across the board. The team has grown a lot. At this point in time, we are 300 people with 40 people outside the US. This is our historic sort of record. We've sold three six different companies to Boston Scientific, Covidien, Abbott, and j&j. And all these companies really are in the cardiovascular space. And that's still our biggest area of focus. The current portfolio is as follows. We have five cardiovascular companies, two ophthalmology companies and one enterprise software company. And I'll walk through very briefly what each one is about. So a dona medical is an adjustable interatrial shunt with integrated by chamber pressure sensors. So it means there are two sensors, and a shunt for patients who have heart failure, that allows the physician to adjust the size of the shunt. So for those patients who have heart failure, and there's a lot of pressure on the left side, and you want to push some of it out to the right side. That's what this is for. And it's a state of the art sort of the next generation technology of devices that are currently in clinical trials. It's a very large opportunity, probably over $6 billion. Ultimately, a lot of patients need this and there's not a lot of really good solutions for heart failure. And we've raised $63 million. So far. There's 40 employees, and it's in a preclinical stage. A core medical is a thrombectomy system. It's a really comprehensive solution. It's a very large market. We've raised $27 million. We have 27 employees and this company has reached the clinical stage. Lazar medical is a robotic innovation for the cath lab. It's a very large opportunity. We are 20 people and it's in the preclinical stage. So paramedical is a low profile 10 French continuous flow, a p value for high risk BCI in cardiac cardiogenic shock. We are 56 employees, and we're in the clinic Dialga cardiovascular is a really nice solution for mitral and tricuspid replacement. We're 50 people and we're in a preclinical stage. A two year vision is a dual optic accomodate intraocular lens 33 People in the clinical stage. And my revision is a glaucoma shot 23 people in a preclinical stage and last, and Lille is a 24 by seven cloud based software for medtech. This is for procurement quality and manufacturing. There's 46 people, and we're in a limited market release at this point. And that concludes my talk.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
